- 3 minutes ago
Η υγεία στην Ευρώπη: δικαίωμα ή επιχειρηματικό μοντέλο; Αντιπαράθεση ευρωβουλευτών στο The Ring
Ειδική έκδοση του The Ring από το Euronews Health Summit: οι ευρωβουλευτίνες Stine Bosse (Renew Europe) και Tilly Metz (The Greens/EFA) αντιπαρατίθενται για το ποιος πρέπει να πληρώνει για την ευρωπαϊκή καινοτομία στην υγεία.
ΔΙΑΒΑΣΤΕ ΕΠΙΣΗΣ : http://gr.euronews.com/2026/03/19/h-ygeia-sthn-eyrwph-dikaiwma-h-epixeirhmatiko-montelo-antipara8esh-eyrwboyleytwn-sto-the
Γίνε συνδρομητής! ! Το euronews είναι διαθέσιμο σε 12 γλώσσες
Ειδική έκδοση του The Ring από το Euronews Health Summit: οι ευρωβουλευτίνες Stine Bosse (Renew Europe) και Tilly Metz (The Greens/EFA) αντιπαρατίθενται για το ποιος πρέπει να πληρώνει για την ευρωπαϊκή καινοτομία στην υγεία.
ΔΙΑΒΑΣΤΕ ΕΠΙΣΗΣ : http://gr.euronews.com/2026/03/19/h-ygeia-sthn-eyrwph-dikaiwma-h-epixeirhmatiko-montelo-antipara8esh-eyrwboyleytwn-sto-the
Γίνε συνδρομητής! ! Το euronews είναι διαθέσιμο σε 12 γλώσσες
Category
🗞
NewsTranscript
00:10Υπότιτλοι AUTHORWAVE
00:30And who should pay?
00:32Europe is facing spiralling healthcare costs
00:34driven by an ageing population and chronic diseases.
00:38At the same time, demand for new treatments is growing,
00:42raising crucial questions.
00:44Who should pay for healthcare innovation?
00:46And to what extent is health treated as a business?
00:50One key pressure point is the cost of new drugs and vaccines.
00:54Should the EU coordinate pricing for essential medicines
00:57to ensure equal access across member states
01:00while also having tools to intervene in production and distribution during crises?
01:05Or should pricing and supply remain a national responsibility
01:09to prevent straining healthcare budgets and weakening market incentives?
01:14Tax debates in the pharmaceutical sector further highlight concerns
01:18about how much the industry should profit from public investment.
01:21Europe also faces longer-term challenges.
01:25Its healthcare system spends far more on treatment than prevention.
01:29The real question is not only how Europe will pay for healthcare,
01:33but what kind of healthcare system it ultimately wants to protect.
01:38Let's meet our panelists.
01:41Tilly Metz, a Luxembourgish MEP from the Greens European Free Alliance Group.
01:47She has been a member of the European Parliament since 2018
01:50and serves on the Committee on the Environment, Public Health and Food Safety.
01:55In debates on EU health policy,
01:57she has advocated for stronger European cooperation on public health
02:01and greater transparency in the pharmaceutical sector.
02:04We need a strong commitment to solidarity over privatization
02:08and to high-quality care over commercialization, she said.
02:13Stine Boss, a Danish MEP from the Liberal Renew Europe Group.
02:17Elected to the European Parliament in 2024,
02:20she works on economic and industry-related issues
02:23and has spoken about the importance of maintaining Europe's competitiveness
02:26and innovation capacity.
02:28In discussions about the pharmaceutical sector,
02:30she has emphasized the need to balance strong research incentives
02:34with sustainable healthcare systems.
02:36We must do much more, better and cheaper together,
02:40including by creating a single market for clinical trials
02:43and by taking more decisions at the European level, she said.
02:50Welcome.
02:51So lovely to have you with us here for this very special edition of The Ring.
02:55So the idea here, ladies, is to give our viewers back home
02:59a bit of a taste of what exactly you get up to
03:01inside that European Parliament chamber,
03:04here in Brussels and also in Strasbourg.
03:07Sometimes you fire questions at each other,
03:09sometimes it gets a little bit heated.
03:11Today, as you know, we're focusing on healthcare
03:14and the future of it right here in the European Union
03:17and who, of course, should pay.
03:18So Tilly, if we can start with you on that very, very pertinent question,
03:22who should be paying for the future of healthcare in Europe?
03:25Should it be us, the patients?
03:26Should it be pharma, the governments, big tech?
03:29Yeah, but if we look what the situation is right now,
03:33we see there's a lot of public funding indeed going in research,
03:37but there's also the patient that is paying.
03:40So you could even say that the patient right now is paying twice.
03:43He is paying first with taxes, which go then to funds,
03:49and then he pays again a price at the pharmacy.
03:51So what we need for sure is at the EU level,
03:55but also at national level, more public investment, yeah.
03:59Well, it actually all connects.
04:01And I do agree that there is an issue on how do we look into the future?
04:08What is the construction?
04:09Is it all, you know, everybody has access to healthcare,
04:13or is it a different model?
04:15That has to be debated.
04:16But at the end of the day, it all starts and it all ends at the end of the day
04:21that we have a strong and competitive pharmaceutical sector,
04:24and then we can disguise who pays.
04:27And that's an important point, of course, Tilly Mets, if you look at the data,
04:32one in every two medicines, this is back 25 years ago,
04:35was invented or discovered right here in Europe.
04:38Now it's only one in six.
04:39What went wrong?
04:41Exactly.
04:42I mean, if we go more to privatization
04:44and more leaving all the leadership to the pharma industry,
04:48we see that it doesn't work.
04:50Indeed, we still have innovation in Europe.
04:52We still have, but we are not really scaling up.
04:54But if we look at innovation and there is no real added value for the patients,
05:00that's something we need to do better.
05:02So it's up to public authorities to take back their leadership
05:07and their responsibility.
05:09I mean, if we go more and more in private healthcare,
05:13there is a huge risk of even more commercialization of access to healthcare
05:19and of commodifying medicines and healthcare.
05:22Would you agree with that point, Sinebos?
05:24Yes, I do agree, but I don't think that a strong pharmaceutical sector
05:29is the opposite of having a totally sane and fantastic healthcare sector as such.
05:36I think these two things go hand in hand.
05:39But that is, of course, a question of funding.
05:41First of all, importantly enough, funding for the pharmaceutical sector,
05:45and then, of course, who pays?
05:47Is it tax paid?
05:48Is it universal access to treatment and to medicines?
05:52Or is it a private sector that we see growing?
05:55And there, I think we will have to face that there will be a blend.
06:00I am a strong believer in a strong universal healthcare sector
06:06that makes sure that there is access for everybody.
06:09I mean, we know that the private sector and the objective of the private sector
06:14are not necessarily aligned with what is really the public health's need.
06:20But I agree, we need a strong pharma sector.
06:24We need to have manufacturing back in Europe, and we need to have the conditions.
06:29But the incentives for the pharma industry must not rely only on intellectual property rights.
06:37There are other models, other alternatives of incentives.
06:41There needs to be a better coordination from the public authority in order to make it more equal.
06:48And this issue of scaling up, how can we do better here?
06:51I mean, in Europe, we're great at research, we're great in the lab,
06:54but getting it to market then is always the big challenge.
06:56Yeah, and there I tend to disagree.
06:59So without letting go of the security level for our citizens,
07:04we should base much more on our EMA and less on our national entities.
07:11Because if you look at it, it is 578 days from the approval of a medicine in EMA,
07:21till it reaches the patient.
07:23And on the European Medicine Agency, we'll come back to that point.
07:25I didn't say that it should not be the European Medicine Agency.
07:28I'm very pro-European.
07:29On the contrary, we need better cooperation between the member states,
07:33and that can only be done at the European level.
07:36I mean, on that I agree with you.
07:38And is the European Union ready for the next big pandemic?
07:41Because we know it's coming.
07:42I mean, we remember those terrible days of COVID,
07:44and we're being warned that the next pandemic is around the corner.
07:47Sinebos, is the EU ready for this?
07:49No.
07:49I mean, we are more prepared than we were.
07:52I mean, we have learned.
07:54And the institutions are also now stronger, and health is a stronger issue.
08:00You know, the fact that we now have the health committee,
08:02and it's a full committee, and so on.
08:04All these things point in the right direction.
08:06That's not reassuring our viewers, just having a committee.
08:08No, I agree.
08:09And here, I'm back to that we need also a stronger collaboration
08:13between countries within the union.
08:17We need links also for ongoing health care,
08:20not only on the innovation side,
08:22but also on the delivery side, also between the hospitals.
08:25There are so many things that we can do a lot better and cheaper together
08:30if we work pan-European on these subjects.
08:34But I think one thing that we definitely learned from the pandemic
08:37is that we are over-reliant to the pharma industry.
08:41So we need the public sector to take more responsibilities again
08:45and to have a better coordination.
08:46To be too reliant to the pharma industry,
08:50I mean, that gives a lot of insecurities also regarding the supply chain,
08:54regarding the transparency on the real coast, on research and development.
08:59I mean, I'm not against a strong pharma industry,
09:02but we must definitely also consider to have a European infrastructure
09:07on research and on production also of medicine.
09:11And I think we need to be ambitious there
09:14in order not to be too reliant and dependent
09:17only on the private sector,
09:20where we all agree that they have different objectives
09:24and that is also perfectly okay.
09:26I mean, as I say, they are not necessarily aligned
09:29with what is really an added value of the medication.
09:32That's why there are certain sectors,
09:35like the orphan medicines, but also the antibiotics,
09:38where the pharma industry is not really interested
09:41because it's not really financially interested.
09:44So your objectives are different
09:45and that's why we need a stronger public leadership of public authorities.
09:50That's the view from Thierry Metz.
09:51Let's hear your view there.
09:52You might have recalled that I'm not a socialist,
09:55but I do have a lot of social responsibility
09:59within the way I think about our citizens.
10:02So I cannot see, Thierry,
10:05that we should go for a fantastic publicly owned pharmaceutical sector.
10:11I think we need a strong, privately owned,
10:14privately financed pharmaceutical sector
10:17who can see the benefits of staying in Europe,
10:20developing in Europe and delivering in Europe.
10:22And we also, of course, want to hear from you.
10:24You can always write to us at the ring at uranus.com.
10:27We'll come back to it.
10:28Okay.
10:32Now it is time for our viewers to get a real taste
10:35of Inside the Chamber
10:36when MEPs actually fire questions at each other.
10:39So now I'd like you to start with your first question for Thierry Metz.
10:42Well, Thierry, I just want to know
10:45how on earth are you going to make sure
10:48that we can be able from Europe
10:50to deliver the best, the newest medicines,
10:55the fastest to our citizens?
10:58What is your prescription for that?
11:00I think it's very clear that we need to give incentives
11:05to the pharma industry
11:06and, on the other hand,
11:07to have kind of safe net by a public infrastructure.
11:12In order to have innovation
11:14and to guarantee also accessibility
11:16to innovation to everybody,
11:19we need to put conditions on this public funding
11:23and we need public authorities
11:26to play their role
11:27on asking accountability to the pharma industry
11:31and on asking transparency
11:33on the R&D costs,
11:36but also on how they develop their prices.
11:38I mean, as I said at the very beginning,
11:41it cannot be that the patient pays
11:43two times or three times,
11:45once by the data,
11:46once by the taxes that he pays,
11:49and then again a high price at the pharmacy.
11:52Are you satisfied with that answer
11:53or would you like to follow up?
11:55No, because I still see
11:57that there is a high risk
11:59with all your good ideas,
12:00some of them we can agree on,
12:01but there is a high risk
12:02that the pharmaceutical sector
12:04would look to other grounds
12:06and say, you know,
12:07it's much more attractive to us
12:09to develop and to invest in the US,
12:12for example, so bye-bye.
12:14I don't see you...
12:14Do you agree with the US system
12:16where indeed the pharma industry
12:19wants to put very much higher prices?
12:21I mean, that's what they want.
12:23That's why they are attracted
12:24by the market in the US.
12:25Is that the model that we should aim at?
12:28No.
12:28Where only an elite can offer treatment
12:31and have innovation access
12:33and innovative healthcare?
12:35No, I think we must definitely
12:37take our responsibility,
12:39and that is one of the lessons learned
12:41from the pandemic.
12:42And that is, Stina,
12:43that's what we are working on,
12:44the Critical Medicines Act.
12:46It's exactly what we are doing there.
12:48we are making that
12:49the EU takes more responsibility
12:51in coordination,
12:54what is critical medicine
12:55for the citizens
12:56and what is really also
12:58of an added value
12:59and how we can bring back manufacturing
13:01again back to Europe.
13:03That's what we are working on,
13:05on the Critical Medicines Act.
13:06And our viewers can read more
13:07about that Critical Medicines Act
13:08on euronews.com.
13:09But now, Tilly Mets,
13:10it is time for you to address
13:11your very first question,
13:12to Stine Boss.
13:13Yeah, but my very first question,
13:15I said it already a little bit,
13:16is like,
13:17do you agree,
13:18in order to have accessibility
13:20and affordability on medicine,
13:22that we need to have
13:25more transparency on coast?
13:27And that is meaning
13:28when we give public funding
13:30to the pharma industry,
13:31that we need to put conditions
13:33on this public funding.
13:36Conditions like supply chain,
13:38transparency on coast, etc.
13:42I think, first of all,
13:43and I will be repeating myself slightly,
13:45so bear with me,
13:47I think that it's the starting point
13:48will be that we have
13:49a strong pharmaceutical sector.
13:51And you might not agree,
13:52you think you jump right into
13:54it has to be state-owned
13:55and it has to be state-funded.
13:57I'm on another page there.
13:58Then, having said that,
14:00then I agree that there are areas,
14:03the Critical Medicines Act
14:04is a good example,
14:05but there are also other areas
14:07where we have to think differently
14:09as Europeans,
14:10but also as countries.
14:12And that's why this thing
14:14about the nearly 600 days
14:16to approval,
14:17that we have to get out.
14:19We need to make sure
14:21that the country's level of approval
14:23is not there.
14:25It doesn't make any difference.
14:27And then on top of that,
14:28if we say to ourselves
14:29that there's an 80% difference
14:31between the countries
14:32of the accessibility to medicines,
14:35of course that cannot be so.
14:37So we have a huge issue
14:39at our hands
14:40to level this out
14:41between countries
14:42and to protect
14:43our universal healthcare.
14:45But that is only protected
14:47if we have earnings.
14:49Earnings makes taxes.
14:50Taxes makes the money
14:52to actually finance healthcare.
14:55I know you had another long list
14:56of questions for each other,
14:58but we will have to wrap it there
14:59because we've now heard
15:01from our MEPs
15:02and I would really like
15:03to bring in another voice here.
15:08I would like to bring in
15:09the voice now
15:10of the head of AstraZeneca,
15:12the CEO and Executive Director,
15:14that's Pascal Sochiot.
15:15He recently said
15:16that the pharma industry
15:18in Europe
15:18will be reduced
15:19to a shadow of itself
15:21within 15 years.
15:22He said this
15:23due to two major threats
15:24facing the pharma industry.
15:26One,
15:27pharma companies
15:28are investing heavily
15:28in the US
15:29to avoid heavy taxes
15:30by the Trump administration.
15:32And of course,
15:33the other elephant in the room,
15:34China,
15:35is of course
15:35the leader in generics
15:37and a major competitor
15:38when it comes
15:38to innovation medicines.
15:40So Tilly Metz,
15:41I'm curious to hear
15:42your view here
15:43on the concerns
15:44of the industry
15:45and of the CEO
15:46there of AstraZeneca.
15:47First of all,
15:48what I want to correct
15:49because it seems like
15:50I want 100%
15:53only state-owned
15:54pharma industry.
15:55That is wrong.
15:56I just want
15:57a safe net
15:59that is public
16:00in order to guarantee
16:01that we are not
16:02100% lying.
16:04But the pharma industry
16:06has an important role
16:08to play
16:08and I spoke about incentives.
16:10I'm just convinced
16:12and we see it
16:13in the reality
16:13if we are pragmatic,
16:15we see in the reality
16:17leaving it all
16:18to the pharma industry
16:19that the system
16:20doesn't work
16:20because we have
16:21shortage of medicine,
16:22et cetera,
16:23what I said before.
16:25But we need
16:26other incentives
16:27like the subscription model
16:28where you know
16:29if you work on research,
16:31for example,
16:31on antibiotics,
16:32that you get
16:33a fixed amount
16:34of money
16:35in order to work on that.
16:37That is one model
16:37or a milestone model.
16:39So...
16:40And Sine-Bos,
16:41if I can just
16:41bring you in here,
16:43I mean,
16:43is it scaremongering
16:44what he says there
16:45or would you agree
16:45with it?
16:46Because I mean,
16:47you're still the home
16:48of a big pharma.
16:49And I think
16:49it's actually more serious
16:50than we can dream of.
16:52We are,
16:53and this is a little bit
16:54dramatic,
16:54but it's good on television,
16:56we are under attack.
16:58I mean,
16:59our pharmaceutical sector
17:00is under attack.
17:01This idea
17:03of the nation,
17:06most favored nation,
17:08legislation
17:08that the administration
17:10in the U.S.
17:12put in place
17:12is really,
17:14really hammering us.
17:15And I'm not saying
17:17that we should give up,
17:18and I agree with you
17:19on the fact
17:20that there should be
17:21a basis coverage,
17:22obviously,
17:22for citizens in Europe,
17:24also regarding the safety
17:25of the approvals.
17:27But we have to understand
17:29that we must fight this
17:31with giving terms
17:33and conditions
17:34to our pharmaceutical sector
17:36that can compete
17:37with this,
17:38in my opinion,
17:39very mean model,
17:40and that we have
17:41to fight back.
17:42Would you agree with this,
17:43what she calls
17:43a very dramatic statement?
17:44Let's look what is
17:45at the center
17:46of our concerns.
17:48And I am allowing myself
17:49to say that it is different
17:50as a politician
17:51than from the pharma
17:52industry perspective.
17:54At the center
17:55of our concern
17:56is the patient.
17:57If you look at
17:57the situation
17:58of the patients
17:59in the United States,
18:00they are in a much
18:01worse health situation.
18:04If you look mental health,
18:05if you look obesity,
18:06if you look at
18:07a lot of diseases,
18:08suicide,
18:09everything,
18:10they are in a much
18:11worse case.
18:12What do I have
18:13from innovation
18:14if it's not accessible
18:15for the large public?
18:17And in innovation,
18:18we are not bad
18:19in Europe.
18:20It's in scaling up,
18:21it's in manufacturing
18:22where we are leaking.
18:23And we have a very
18:24fragmented market
18:25as well,
18:25Sinebos.
18:26Sure,
18:26we have this
18:27fragmented market
18:28and we have really
18:30not a capital union,
18:31right?
18:31So we need also
18:33the fact that
18:33investors should have
18:35a much,
18:36yeah,
18:36investors and companies
18:37much easier access
18:39to capital
18:39to make them stay here.
18:41We also have to face,
18:43Tilly,
18:44that no matter
18:44how we turn this around,
18:46there needs to be
18:48a strong sector here.
18:49we need to understand
18:50what the problems
18:51is for the sector,
18:52try and solve them,
18:54and then of course
18:54fight back to the US
18:55because I agree,
18:56even long liberty
18:57is much better in Europe
18:58and we should not
18:59give up on these areas
19:01but it's not
19:02on the contrary
19:03to have a strong sector.
19:05And then it comes back
19:06to the first question,
19:07who is paying?
19:08And there I think
19:09there is a need
19:11for a truly
19:12and deep discussion
19:14on transparency,
19:15on how do we
19:16actually have fun
19:17because our model,
19:18look,
19:19our model is like
19:2180% gets everything,
19:23right?
19:23We covered a lot of people.
19:25That's why we buy
19:27a lot of pharmaceutical products
19:28at a cheap price.
19:30In the US,
19:31not a lot of people
19:32are covered
19:33so they pay much more
19:34per pill.
19:36So that makes it
19:37completely uncomparable
19:38and that we have
19:40to sit down
19:40and really investigate
19:42and find out
19:43also in the Biotech Act,
19:44how are we going
19:45to solve this?
19:46So you have a lot
19:47to do ladies
19:48but now it is time
19:49in fact for our
19:50next round.
20:00Now I'd like to bring in
20:01some figures.
20:02There is a big problem
20:03when it comes to Europeans
20:04having to wait
20:05for new medicines.
20:06The EU average
20:07is about 578 days.
20:10That's from approval
20:11to patient access.
20:13And it varies
20:14from country to country.
20:15Patients in some countries
20:17have to wait
20:17seven times longer
20:19than others.
20:20While the fastest
20:21is in Germany
20:22at 128 days,
20:24Portuguese patients
20:25wait the longest.
20:26So your reaction here
20:27to this inequality?
20:28Yeah, this is
20:31completely how it is.
20:32But of course
20:33there is an explanation.
20:35It's not because
20:36Portugal wants
20:37to have
20:38a longer period
20:40for the population.
20:41It's about finances.
20:42It's about
20:43can they afford it?
20:44And here we are
20:45of course entering
20:45into very, very
20:46difficult discussions
20:48because a country
20:49like Denmark,
20:50if you compare us
20:51to Bulgaria,
20:52to Romania,
20:53then we are in
20:54for big,
20:55you know,
20:56there's a big difference.
20:57and that we need
20:58to over time
20:59solve.
21:00But one of the ways
21:01to do it
21:02is to again
21:02what we can make
21:04better and cheaper
21:05together we must,
21:06including the EMA,
21:07to save all the money
21:08in all the countries.
21:10And the irony is
21:11in Germany,
21:12128 days,
21:13that's supposed
21:13to be quick.
21:14I mean,
21:14that's a matter
21:14of life and death
21:15if you have to wait
21:15that long
21:16for your pills.
21:16Yes.
21:17Yeah,
21:18indeed.
21:18And what we need
21:19also is
21:20we need more
21:21cooperation
21:22in European
21:23procurement
21:24so that we do,
21:26that we buy
21:27together
21:27in order
21:28also with strict
21:29timeline
21:30and also with
21:31the security
21:31on the supply chain.
21:33So that's again,
21:34we need to give
21:35more incentives,
21:36that is true,
21:37but that goes
21:38hands in hand
21:39with conditions
21:40of supply chain,
21:41et cetera.
21:42And we need,
21:43of course,
21:44on that I agree
21:44with Cinebos,
21:45we need also
21:46to keep the EMA,
21:47the European Medicines Agency,
21:49more human resources
21:50and more resources
21:51in general
21:52in order
21:53to be more efficient
21:54and then
21:54that we need
21:55less and less
21:56also there
21:56to rely
21:57on national issues.
21:59And should there
22:00be an EU-wide
22:01pricing
22:01for essential medicines?
22:02I think
22:03at the end
22:04of the day
22:04we will get
22:05into that area.
22:07I don't see
22:08that we can avoid
22:09having some kind
22:10of more transparency
22:12and more central
22:13discussed price.
22:15Because now
22:15when you go
22:15to your doctor
22:16sometimes they say
22:16go to France
22:17you can get
22:17to France.
22:18Yeah, yeah, yeah, yeah.
22:19That's why I say
22:19but I had this
22:20conversation with
22:21you can probably
22:22guess who it is
22:23but it was
22:24a CEO
22:24of a large
22:25Danish pharmaceutical
22:26company
22:27and I said
22:28to him
22:29I don't worry
22:30when I go
22:30in a shop
22:31and I buy
22:32like say
22:32H&M
22:33and I buy
22:34something
22:34and I can see
22:35the price
22:36in Sweden
22:36in Germany
22:37in France
22:38and I'm still
22:39happy paying
22:40with my
22:40unfortunately
22:41it's still
22:41Danish krona
22:43so
22:44I think
22:45we should be
22:45more transparent
22:47we should be
22:47more bold
22:48together with
22:50the industry
22:50and they are
22:51also
22:51at least
22:52some of them
22:53maturing
22:53in that direction
22:55of course
22:55also because
22:56of the big threat
22:57that we have
22:58just debated
22:58from the outside
22:59now we definitely
23:00need to put
23:01public interest
23:02is definitely
23:03more important
23:04especially in the
23:04health sector
23:05than commercial
23:06interest
23:07I mean at the
23:07very end
23:08the very famous
23:10company
23:11pharma industry
23:11that produced
23:12drugs in
23:12in the last
23:13moment the price
23:14was really
23:15increasing again
23:16why?
23:16all the research
23:17all the A&D
23:18was done
23:19so we need
23:19definitely
23:20transparency
23:20and as I said
23:21that goes
23:22hand in hand
23:23with also
23:24public funding
23:25it's something
23:26we owe
23:26to the taxpayers
23:27we owe to the citizens
23:29to ask for this
23:30transparency
23:31and especially
23:32when we speak
23:33of a fundamental
23:33right
23:34which is access
23:35to health care
23:36because as you said
23:37twice or three times
23:38or four times
23:39already here in the
23:40program
23:40consumers are paying
23:41twice
23:42patients are paying
23:42twice
23:43this is a big
23:43problem
23:44well I'm not sure
23:45I agree completely
23:46on the fact
23:47that people are
23:48paying twice
23:50I agree
23:50that there is a
23:52debate on how
23:53can we make
23:53this more transparent
23:54but to be honest
23:55I mean the
23:56pharmaceutical sector
23:58invests a lot
23:59and they should
24:00and I also agree
24:02that in some areas
24:03they should also
24:03be held accountable
24:04you know
24:05if there is
24:06public money
24:07involved
24:07yes
24:08I agree on that
24:09shall we speak
24:09about the benefits
24:10that we made
24:11for the COVID-19
24:12yes
24:13but look
24:13then on the
24:14other hand
24:15of course
24:15there is
24:16large number
24:17of workplaces
24:19innovation
24:20you know
24:21attracting
24:22skilled people
24:23and all this
24:24is also beneficial
24:25for Europe
24:26it's not only
24:26it's not a
24:28non-sum
24:28spill
24:28you know
24:30thing
24:30we have to
24:31look at the
24:32total
24:32and I think
24:33it is
24:34it would be
24:35devastating
24:35if we lost
24:36the last industry
24:37ladies and
24:38gentlemen
24:39the last industry
24:40where we are
24:41still close to
24:42not even
24:43but close to
24:44on par
24:45with the US
24:46and China
24:47we lost
24:48digital industry
24:49so do we want
24:50in 10 years
24:51from now
24:52to have a
24:52pharmaceutical sector
24:53where we said
24:53that's history
24:54it's gone
24:54and on the
24:55digital industry
24:56that's of course
24:56for another episode
24:57of The Ring
24:57we'll have to
24:58wrap it up there
24:58because I would
24:59love to move
25:00on to the
25:00fifth
25:01and very last
25:02round of this
25:03very special
25:03edition of The Ring
25:04which is focusing
25:05on the future
25:05of healthcare
25:10ladies
25:10are you ready
25:11yeah
25:11excellent
25:12because you need
25:13all your wits
25:14about you
25:14for this last
25:15segment
25:16because it's
25:16a little bit
25:17different
25:17you only are
25:18allowed answer
25:19using yes
25:20or no
25:21does that sound
25:21good
25:22that sounds good
25:23great let's do it
25:24Stine Boss
25:25let's begin with you
25:26should the EU
25:26cap prices
25:27for essential
25:28medicines
25:29yes or no
25:35can I have a
25:36yes but
25:36very briefly
25:38yes
25:39but it has
25:40to be limited
25:41to very very
25:42special situations
25:43and very special
25:44medicines
25:44okay let's see
25:45if you can do
25:45a yes or no
25:46here
25:46yes
25:47it's a fundamental
25:47right
25:48access to
25:48fundamental
25:49medicines
25:49is a fundamental
25:50right
25:51another question
25:52coming for you
25:53both
25:53Tilly
25:53I will start
25:54with you
25:54should Brussels
25:55negotiate
25:55drug prices
25:56for all
25:56EU member states
25:58I think
25:58that would be
25:59a strength
25:59if we do
26:00that
26:00we saw
26:00the COVID-19
26:01that negotiating
26:03together
26:04gives us
26:04more power
26:05so yes
26:05so that's a yes
26:06what about you
26:07yes or no
26:07on this one
26:08down the road
26:09it will be a yes
26:10from me also
26:11should patents
26:12be waived
26:13during major
26:14health crises
26:15yeah yeah
26:15of course
26:16I mean the
26:16patients
26:17and this is
26:17yes
26:18I say yes
26:19to the fact
26:20that you
26:21you need
26:21we need
26:22we're politicians
26:23we need
26:23to keep
26:24our main
26:24focus
26:25on the
26:25patients
26:26no doubt
26:26about that
26:27and now a
26:28question
26:28you're both
26:28going to love
26:29should medicines
26:29be the same
26:30price all across
26:31the European
26:31Union
26:32that's a long
26:33way to go
26:34there but
26:35that would be
26:36coherent
26:37if we listen
26:38to the
26:38European citizens
26:39step one
26:40more health care
26:41and also
26:42that's a big yes
26:43a resigning yes
26:43what about you
26:44I mean it goes
26:45hand in hand
26:46with what I just
26:47answered
26:47so if you have
26:48if you have
26:49a procurement
26:50way down the road
26:51that is common
26:52European
26:53then of course
26:54you also have
26:54a transparent
26:55common
26:55and just finally
26:56is the future
26:57of EU health
26:58and innovation
26:59bright
27:01yes
27:02I'm a strong
27:03believer
27:04in the EU
27:04as such
27:05and of course
27:05also in this sector
27:06but we have to get
27:07a lot of our act
27:08together
27:08and what about you
27:09yes or no
27:09bright future
27:10or not
27:10yes or no
27:11yes because we
27:12should listen
27:13to the citizens
27:14and we should
27:14put more funding
27:15and not cut
27:16the funding
27:17did you agree
27:17with anything
27:17you've heard
27:18yes she said
27:19that we should
27:19waive the
27:20intellectual property
27:21rights during
27:22a pandemic
27:22there you go
27:23you see it's
27:23here on the ring
27:24where we get
27:24people to talk
27:25disagree
27:26and sometimes
27:27agree
27:27thank you so much
27:28and a round of applause
27:28for our two
27:29MEPs on the ring
27:30Stine Boss
27:31and Tony Metz
27:32thank you
27:37and thank you
27:38so much
27:38for tuning in
27:39as always
27:39we love to hear
27:40from you
27:40write to us
27:41at the ring
27:41at Euronews.com
27:43and stay with us
27:43here on Euronews
27:45MEPs on the ring
Comments